Skip to Content
Merck
All Photos(2)

Documents

M0696

Sigma-Aldrich

Anti-MNK2 (N-terminal) antibody produced in rabbit

enhanced validation

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-GPRK7, Anti-MAP kinase interacting serine/threonine kinase 2, Anti-MKNK2

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.44

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen ~50 kDa

species reactivity

rat (predicted), human, mouse (predicted)

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation

concentration

~1.0 mg/mL

technique(s)

immunocytochemistry: 2-5 μg/mL using paraformadehyde fixed HEK-293T cells transfected with human MNK2
immunoprecipitation (IP): 2-4 μg using lysates of HEK-293T cells transfected with human MNK2
indirect immunofluorescence: suitable
western blot: 1-2 μg/mL using lysates of HEK-293T cells transfected with human MNK2

UniProt accession no.

Q9HBH9

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... MKNK2(2872)
mouse ... Mknk2(17347)
rat ... Mknk2(299618)

Related Categories

General description

MNK2 is a serine threonine kinase that phosphorylates endogenous eIF4E and thereby regulates protein translation and cell growth. This kinase inhibits apoptotic responses induced by arsenic trioxide. MNK2 has two distinct splice forms, namely; MNK2a and MNK2b. The localization and function of MNK2 splice variants are directed by their N and C termini . Anti-MNK2 (N-terminal) antibody is specific for human MNK2. The antibody is also expected to react with mouse and rat MNK2. In immunoblotting, staining of the MNK2 band is specifically inhibited by the immunizing peptide.

Immunogen

synthetic peptide corresponding to amino acids 51-64 of human MNK2 (corresponding to isoforms 1 and 2), conjugated to KLH via a C-terminal added cysteine residue. The corresponding sequence is conserved in human, rat, and mouse.

Application

Anti-MNK2 (N-terminal) antibody is suitable for use in immunocytochemistry (2-5 μg/mL using paraformaldehyde fixed, MNK2-transfected, HEK-293T cells) and indirect immunofluorescence. The antibody may also be used for immunoprecipitation (2-4 μg) and western blot (1-2 μg/mL) using lysates of HEK-293T cells transfected with human MNK2.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Y Shi et al.
Oncogene, 32(2), 190-197 (2012-03-01)
When mTOR inhibitor rapalogs prevent cap-dependent translation of cell-cycle proteins like c-myc, continuing tumor cell growth depends on cap-independent translation, which is mediated by internal ribosome entry sites (IRESes) located in the 5'-UTR (untranslated region) of transcripts. To investigate if
Senthilmurugan Ramalingam et al.
Cancers, 11(3) (2019-03-06)
Currently, there are no effective therapies for patients with triple-negative breast cancer (TNBC), an aggressive and highly metastatic disease. Activation of eukaryotic initiation factor 4E (eIF4E) by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) play a critical role
G C Scheper et al.
Molecular and cellular biology, 21(3), 743-754 (2001-01-12)
The cap-binding translation initiation factor eukaryotic initiation factor 4E (eIF4E) is phosphorylated in vivo at Ser209 in response to a variety of stimuli. In this paper, we show that the mitogen-activated protein kinase (MAPK) signal-integrating kinase Mnk2 phosphorylates eIF4E at
Gert C Scheper et al.
Molecular and cellular biology, 23(16), 5692-5705 (2003-08-05)
The cap-binding eukaryotic initiation factor eIF4E is phosphorylated by the mitogen-activated protein (MAP) kinase-interacting kinases (Mnk's). Three forms of the Mnk's exist in human cells: Mnk1, Mnk2a, and Mnk2b. These last two are derived from the same gene by alternative
U Knauf et al.
Molecular and cellular biology, 21(16), 5500-5511 (2001-07-21)
Eukaryotic initiation factor 4E (eIF4E) is a key component of the translational machinery and an important modulator of cell growth and proliferation. The activity of eIF4E is thought to be regulated by interaction with inhibitory binding proteins (4E-BPs) and phosphorylation
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service